. Drug-free MVs derived from RAW macrophages showed no therapeutic effects. 
. Primers used in this study. 
CCL-2-MUS TTGAGGTGGTTGTGGAAAAGG GTGCTGACCCCAAGAAGGAAT

TNF-α-MUS AGACAGAGGCAACCTGACCAC GCACCACCATCAAGGACTCAA
IL-1β-MUS
GGTAAGTGGTTGCCCATCAGA GTCGCTCAGGGTCACAAGAAA
IL-6-MUS GTCACCAGCATCAGTCCCAAG CCCACCAAGAACGATAGTCAA
Star-MUS AAGAGCTCAACTGGAGAGCAC TACTTAGCACTTCGTCCCCGT
Cyp1b1-MUS TCCTCTCTGCCGAAAAGAAA ACAACCTGGTCCAACTCAGC
Cyp21-MUS AGACCCTTCACGACTGTGTC AGACCCTTCACGACTGTGTC
Fig.1 Characterization of RAW 264.7 macrophages-derived DEX-packaging MVs.
(A) RAW cells were incubated with DEX and then supernatants were subjected to differential centrifugation. Brief protocol: centrifugation at 2000 × g for 20 min to remove cell debris and apoptotic bodies, followed by centrifugation at 16,500 × g for 30 min (16.5K pellet), followed by 100,000 × g for 60 min (100K pellet). Exosomal markers (TSG101 and Alix) were detected in 100K pellet, but not detected in 1.65K pellet, suggesting that the DEX-packaging vesicles we collected were mainly MVs. Related to Fig. 1c. (B) HPLC analysis of the quantity of DEX in MVs. Drug contents of MVs were calculated according to the standard curve. Related to Fig. 1d . (C) The stability of MV-DEX was analyzed under various conditions. MV-DEX were suspended in PBS and treated with different conditions, including put in RT or 37 ℃ for a week, suspended in pH 8.5 or 5.5 solution, dealt with SDS (0.1%, 0.5%) or proteinase K (0.5 μg/L) or Triton-100 (0.1%) for 10 min. MVs were then recollected and counted by NTA. Data are presented as mean ± SD, n=3 independent experiments. To determine whether MV-mediated drug delivery was responsible for this enhancement in vivo, we stored the MV-DEX and free DEX at 37 ℃ for 10 days to destroy most MVs, whereas the drug concentration between two groups remained the same. LPS-induced nephropathy and the treatment protocol was described in detail in the Methods. Serum creatinine (A) and cytokine (TNF-α, IL-6, IL-β and CCL-2) mRNA expression levels (B) were analyzed. n=4 mice per group. NS, not significant, *** p<0.001, # p<0.05, ## p<0.01, ### p<0.001, one-way ANOVA.
Supplementary Figure 6 ADR-induced nephropathy and the treatment protocol was described in detail in the Methods. The liver and kidney were rinsed, weighed, and homogenized in two volumes of lysis buffer (based on tissue weight). DEX concentration in tissue homogenates was determined by HPLC. n=3 mice per group. Data are presented as mean ± SD, * p<0.05, ** p<0.01, two-tailed t-test. (A)(B) Mixed lymphocyte reaction assay was performed to evaluate the immunogenicity of MV-DEX. Splenocytes from BALB/C mice were prepared as stimulator cells and were exposed to ultraviolet irradiation. Splenocytes from ADRtreated C57/B6 mice exposed or not to MV-DEX treatment were used as responder cells (treatment protocol of MV-DEX was described in detail in the Methods). The BALB/C splenocytes were mixed with C57/B6 splenocytes at a ratio of 1:10 in culture medium (RPMI1640 supplemented with 10% FBS). After 6 days of coculture, the proliferation of CD4 T cells was analyzed by flow cytometry (A) and the IFN-γ expression was quantified by ELISA (B). There was no significant difference in CD4 T cell proliferation between the two groups. (C) Flow cytometry analysis profiles of IgM-and IgG-positive MV-DEX, previously incubated with the serum of mice untreated or treated with MV-DEX, which showed no significant elevation of autologous antibody compared to the untreated group. Data are presented as mean ± SD, two-tailed t-test. 
